The rise of targeted therapy for solid tumours over the past decade has yielded a cornucopia of novel agents across an array of cancers. Amidst multiple acclaimed successes, targeted therapies are associated with considerable toxicity, and durable responses are often thwarted by genomic chaos driving the evolution of resistant clones; key examples of successes in solid tumours are highlighted herein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Karapetis, C. S. et al. K-Ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Joensuu, H. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307, 1265–1272 (2012).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.W.N. has received grants for research support from, ArQule, Boehringer-Ingelheim, Merck, and Roche/Genentech. G.W.S. has received grants for research support from Roche/Genentech and honouraria for speaking from Genentech, is a consultant for Symphogen, and is a member of the Board of Directors for Syndax Pharmaceuticals.
Supplementary information
Supplementary Table 1
FDA-approved targeted therapies in solid tumours (DOC 55 kb)
Rights and permissions
About this article
Cite this article
Neal, J., Sledge, G. Successes, toxicities and challenges in solid tumours. Nat Rev Clin Oncol 11, 627–628 (2014). https://doi.org/10.1038/nrclinonc.2014.171
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.171
This article is cited by
-
Banxia Xiexin Decoction (半夏泻心汤) Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review
Chinese Journal of Integrative Medicine (2019)
